We are pleased to announce that our company has been named “Emerging CDMO of the Year” in the Bioprocessing Technologies category at the Asia-Pacific Biopharma Excellence Award (ABEA) 2026.
The ABEA aims to honour exceptional achievements and pioneering leaders who are shaping the future of the biopharmaceutical industry in the Asia-Pacific region. Award recipients are selected based on votes from the biopharma community.
　We believe this award recognizes our efforts in antibody drug manufacturing, including our initiatives in continuous manufacturing. We would like to express our sincere gratitude to the organizers of ABEA 2026, as well as to our customers and partners for their continued support.
　Going forward, we will remain committed to realizing an “Advanced Biomanufacturing Factory” through the integration of cutting-edge manufacturing technologies.

　For more details, please visit the ABEA 2026 organizer’s website .